Premium
The diversity of T‐cell co‐stimulation in the induction of antitumor immunity
Author(s) -
Schlom Jeffrey,
Hodse James W.
Publication year - 1999
Publication title -
immunological reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.839
H-Index - 223
eISSN - 1600-065X
pISSN - 0105-2896
DOI - 10.1111/j.1600-065x.1999.tb01330.x
Subject(s) - biology , major histocompatibility complex , t cell , cd8 , cellular immunity , t cell receptor , antigen , microbiology and biotechnology , immune system , immunology , virology
Summary: T‐cell activation has now been shown to require at least two signals. The first signal is antigen‐specific, is delivered through the T‐cell receptor (TCR) via the peptide/major histocompatibility complex (MHC). and causes the T cell to enter the ceil cycle. The second, or co‐stimulatory, signal is required for cytokine production and proliferation, and is mediated through ligand interaction on the surface of the T cell. This chapter deals with: 1) comparative studies on the use of a dual‐gene construct of a recombinant vaccinia (rV) vector containing a tumor‐associated antigen (TAA) gene and a co‐stimulatory molecule gene vs che use of admixtures of rV‐TAA and rV containing the co‐stimulatory molecule to induce and‐tumor immunity; 2) the use of an admixture of vaccinia viruses containing a lAA gene and the B7‐1 co‐stimulatory molecule gene to induce a therapeutic response in a lung metastasis tumor model: 3) the antitumor efficacy of whole‐tutnor‐cell vaccines in which the B7‐1 co‐stimulatory molecule is expressed in a tumor‐cell vaccine via a vaccinia vs a retroviral vector; 4) the use of recombinant poxviruses containing the genes for the co‐stimulatory molecules tCAM‐l or LFA‐3 to induce antitumor immunity: and 5) the use of poxvirus vectors containing a triad of co‐stimulatory molecules (B7‐1. ICAM‐1 and LFA‐3) that synergize to enhance both CD4 + and CD8+ T‐cell responses to a new threshold.